AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
201.395
+5.805 (+2.97%)
As of 2:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close195.590
Open197.220
Bid201.380 x 1000
Ask201.460 x 900
Day's Range196.460 - 201.480
52 Week Range163.310 - 210.190
Volume1,121,305
Avg. Volume2,508,815
Market Cap130.357B
Beta (3Y Monthly)1.53
PE Ratio (TTM)60.33
EPS (TTM)3.338
Earnings DateOct 30, 2018
Forward Dividend & Yield5.28 (2.67%)
Ex-Dividend Date2018-08-16
1y Target Est205.15
Trade prices are not sourced from all markets
  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance20 hours ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • Benzinga6 hours ago

    The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • Reuters6 hours ago

    Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

    Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.

  • The Wall Street Journal7 hours ago

    [$$] Biosimilar Humira Goes on Sale in Europe, Widening Gap With U.S.

    Cheaper copies of the world’s biggest-selling drug will roll out across Europe this week after a key European patent for Humira expires Tuesday, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug. Inc., that prevents the developers of “biosimilar” versions launching their products in the U.S. Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells in a process that resembles brewing.

  • PR Newswire14 hours ago

    Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe

    THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC).

  • Immune Design to Halt Cancer Vaccine Program, Shares Plunge
    Zacksyesterday

    Immune Design to Halt Cancer Vaccine Program, Shares Plunge

    Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.

  • Top Ranked Income Stocks to Buy for October 15th
    Zacksyesterday

    Top Ranked Income Stocks to Buy for October 15th

    Top Ranked Income Stocks to Buy for October 15th

  • AbbVie Settles With Novartis to Delay Humira Biosimilar in US
    Zacks4 days ago

    AbbVie Settles With Novartis to Delay Humira Biosimilar in US

    AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

  • Reuters5 days ago

    Abbvie settles Humira patent disputes with Novartis unit

    Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.

  • Here's Why Coherus BioSciences Fell 18.1% in September
    Motley Fool5 days ago

    Here's Why Coherus BioSciences Fell 18.1% in September

    Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.

  • Here's Why bluebird bio Dropped 13.3% in September
    Motley Fool5 days ago

    Here's Why bluebird bio Dropped 13.3% in September

    The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist5 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Celgene: Multiple Myeloma Franchise Could Drive Growth
    Market Realist6 days ago

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).

  • Tilary Buys Alef Biotechnology to Build Base in Latin America
    Zacks6 days ago

    Tilary Buys Alef Biotechnology to Build Base in Latin America

    Tilary (TLRY) acquires import and distribution partner, Alef Biotechnology to strengthen its base in Latin America.